首页> 美国卫生研究院文献>Drug Safety - Case Reports >Fatal Vitamin K-Dependent Coagulopathy Associated with Cefoperazone/Sulbactam: A Case Report
【2h】

Fatal Vitamin K-Dependent Coagulopathy Associated with Cefoperazone/Sulbactam: A Case Report

机译:与头孢哌酮/舒巴坦相关的致命性维生素K依赖性凝固性凝血病:病例报告

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

This case report describes a suspected and fatal adverse reaction involving vitamin K-dependent coagulopathy that might be associated with cefoperazone/sulbactam (CPZ/SAM), a combined antimicrobial formulation. We reported a patient diagnosed with acute cerebral infarction and secondary pulmonary infection who was treated with an intravenous infusion of CPZ/SAM at 3 g twice daily. After receiving treatment with CPZ/SAM, the patient developed a fatal adverse reaction of CPZ-induced hemorrhage. The Naranjo assessment score in this report was 5, suggesting that the patient’s coagulation function disorder was potentially associated with the use of CPZ/SAM. To prevent vitamin K-dependent coagulopathy caused by CPZ/SAM, it is suggested to avoid cephalosporins in patients with a high risk of bleeding unless the need for cephalosporins is compelling.
机译:该病例报告描述了涉及维生素K依赖性凝血病的可疑和致命不良反应,可能与头孢哌酮/舒巴坦(CPZ / SAM)(一种联合抗菌制剂)有关。我们报告了一名诊断为急性脑梗死和继发性肺部感染的患者,每天两次静脉注射CPZ / SAM 3g进行治疗。在接受CPZ / SAM治疗后,患者出现了CPZ引起的出血的致命不良反应。该报告中的Naranjo评估得分为5,表明该患者的凝血功能障碍可能与CPZ / SAM的使用有关。为防止CPZ / SAM引起的维生素K依赖性凝血病,除非有强烈的头孢菌素需求,否则建议避免在出血风险高的患者中使用头孢菌素。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号